From genes to pain:: Nav1.7 and human pain disorders

被引:204
|
作者
Dib-Hajj, Sulayman D.
Cummins, Theodore R.
Black, Joel A.
Waxman, Stephen G.
机构
[1] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Ctr Neurosci & Regenerat Res, New Haven, CT 06510 USA
[3] VA Connecticut Healthcare Syst, Rehabil Res Ctr, West Haven, CT 06516 USA
[4] Indiana Univ, Sch Med, Stark Neurosci Inst, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA
关键词
D O I
10.1016/j.tins.2007.08.004
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Gain-of-function mutations or dysregulated expression of voltage-gated sodium channels can produce neuronal hyperexcitability, leading to acute or chronic pain. The sodium channel Na(v)1.7 is expressed preferentially in most slowly conducting nociceptive neurons and in sympathetic neurons. Gain-of-function mutations in the Na(v)1.7 channel lead to DRG neuron hyperexcitability associated with severe pain, whereas loss of the Na(v)1.7 channel in patients leads to indifference to pain. The contribution of Na(v)1.7 to acquired and inherited pain states and the absence of motor, cognitive and cardiac deficits in patients lacking this channel make it an attractive target for the treatment of neuropathic pain.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 50 条
  • [1] NaV1.7: A central role in pain
    Waxman, Stephen G.
    Dib-Hajj, Sulayman D.
    NEURON, 2023, 111 (17) : 2615 - 2617
  • [2] NaV1.7 as a pain target - From gene to pharmacology
    Vetter, Irina
    Deuis, Jennifer R.
    Mueller, Alexander
    Israel, Mathilde R.
    Starobova, Hana
    Zhang, Alan
    Rash, Lachlan D.
    Mobli, Mehdi
    PHARMACOLOGY & THERAPEUTICS, 2017, 172 : 73 - 100
  • [3] Navigating a new path to Nav1.7 for pain
    Katie Kingwell
    Nature Reviews Drug Discovery, 2022, 21 : 18 - 18
  • [4] NaV1.7 and pain: contribution of peripheral nerves
    Hoffmann, Tal
    Sharon, Ohad
    Wittmann, Juergen
    Carr, Richard W.
    Vyshnevska, Alina
    De Col, Roberto
    Nassar, Mohammed A.
    Reeh, Peter W.
    Weidner, Christian
    PAIN, 2018, 159 (03) : 496 - 506
  • [5] No Gain, No Pain: Nav1.7 as an Analgesic Target
    King, Glenn F.
    Vetter, Irina
    ACS CHEMICAL NEUROSCIENCE, 2014, 5 (09): : 749 - 751
  • [6] Nav1.7 withholds its pain potential
    Kingwell, Katie
    NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (05) : 321 - 323
  • [7] Navigating a new path to Nav1.7 for pain
    Kingwell, Katie
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (01) : 18 - 18
  • [8] Nav1.7 inhibitors for the treatment of chronic pain
    McKerrall, Steven J.
    Sutherlin, Daniel P.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (19) : 3141 - 3149
  • [9] Nav1.7 and Nav1.8: Role in the pathophysiology of pain
    Hameed, Shaila
    MOLECULAR PAIN, 2019, 15
  • [10] Sodium channels Nav1.7, Nav1.8 and pain; two distinct mechanisms for Nav1.7 null analgesia
    Iseppon, Federico
    Kanellopoulos, Alexandros H.
    Tian, Naxi
    Zhou, Jun
    Caan, Gozde
    Chiozzi, Riccardo
    Thalassinos, Konstantinos
    Cubuk, Cankut
    Lewis, Myles J.
    Cox, James J.
    Zhao, Jing
    Woods, Christopher G.
    Wood, John N.
    NEUROBIOLOGY OF PAIN, 2024, 16